Sangamo Therapeutics Inc (SGMO) Is A Buy According To Analysts

ZM Stock

Sangamo Therapeutics Inc (NASDAQ:SGMO) has a beta value of 1.24 and has seen 2.92 million shares traded in the last trading session. The company, currently valued at $68.48M, closed the last trade at $0.33 per share which meant it lost -$0.03 on the day or -7.90% during that session. The SGMO stock price is -406.06% off its 52-week high price of $1.67 and 12.12% above the 52-week low of $0.29. The 3-month trading volume is 2.16 million shares.

Sangamo Therapeutics Inc (NASDAQ:SGMO) trade information

Sporting -7.90% in the red in last session, the stock has traded in the red over the last five days, when the SGMO stock price touched $0.33 or saw a rise of 31.03%. Year-to-date, Sangamo Therapeutics Inc shares have moved -39.26%, while the 5-day performance has seen it change -29.76%. Over the past 30 days, the shares of Sangamo Therapeutics Inc (NASDAQ:SGMO) have changed -39.47%.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

Sangamo Therapeutics Inc (SGMO) estimates and forecasts

Figures show that Sangamo Therapeutics Inc shares have underperformed across the wider relevant industry. The company’s shares have lost -44.91% over the past 6 months, with this year growth rate of 6.78%, compared to 15.50% for the industry.

If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was -15.96% over the past 5 years.

SGMO Dividends

Sangamo Therapeutics Inc is expected to release its next earnings report in August this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.